- Business Wire•36 minutes ago
BioTime, Inc. , a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that it will release fourth quarter and fiscal 2016 financial and operating results on Thursday, March 16, 2017, after the close of the U.S.
- Investopedia•21 hours ago
BioTime will post a non-cash gain on the deconsolidation of its OncoCyte unit.
- Zacks•23 hours ago
BioTime, Inc. (BTX) was above 7% in the last trading session.
BTX : Summary for BioTime, Inc. - Yahoo Finance
BioTime, Inc. (BTX)
NYSE MKT - NYSE MKT Delayed Price. Currency in USD
Add to watchlist
|Bid||3.20 x 9700|
|Ask||3.30 x 1900|
|Day's Range||3.18 - 3.31|
|52 Week Range||2.26 - 4.01|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||12.17|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|